Novocure Announces Approval For Optune Lua In Japan
(RTTNews) - Novocure (NVCR) announced that Japan's Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer who have progressed on or after platinum-based chemotherapy. The MHLW approval was supported by the Phase 3 LUNAR trial.
Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields or TTFields, which are delivered through non-invasive, wearable arrays.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.